Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 421-438 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 421 | Camphouse lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Camphouse after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 422 | Capsa AI lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Capsa AI after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 423 | CardNexus lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CardNexus after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 424 | CeQur lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CeQur after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 425 | CITIC Group lowweak | Opp 0 Risk 1 | Thesis: No reviewed sources-supported positive thesis is available. The reviewed sources explicitly says the summaries do not clearly connect CITIC Group to a qualifying space business. Why now: There is no current catalyst. Despite 4,475 article IDs considered, the reviewed sources reports zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase2 rationale references article IDs: and: as context, but no were provided in the reviewed sources. Very large raw mention universe does not imply conviction or thesis attractiveness. Possible name/alias ambiguity is unresolved by the reviewed sources. |
| 426 | COMSAT lowweak | Opp 0 Risk 1 | Thesis: No positive thesis is supported. The reviewed sources rationale says COMSAT appears only in the context of Intuitive Machines acquiring Goonhilly Earth Station/COMSAT, which is indirect and not sufficient for a company-specific opportunity view. Why now: No 90-day article summaries or evidence were available for COMSAT in these reviewed sources, so there is no supported timing catalyst. Caveats: Relations/context-only style mention should not be used as counterparty propagation evidence. Phase2 rationale references article ids: and: but no or summaries are provided in the reviewed sources. No direct evidence were available after recent evidence window. |
| 427 | EaglePicher Technologies lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale says EaglePicher is a key player in space batteries and that its systems were on NASA CLPS lunar lander missions, but no retained direct positive evidence or article summaries are available here. Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set. |
| 428 | Element U.S. Space & Defense lowweak | Opp 0 Risk 1 | Thesis: The reviewed sources only indicates service/testing relevance in a Sidus-related context, and it contains no retained direct positive evidence with inside the recent evidence window, so there is no supported opportunity thesis. Why now: Why now is absent because only 2 articles were considered and none survived the 90-day filter; there is no current evidence basis for a 1 year+ directional call. Caveats: Coverage is extremely sparse. The only described relation is context/service oriented and relations are context-only unless policy-gated. No post-cutoff evidence available. |
| 429 | IHI Corporation lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale references IHI benefiting from ICEYE SAR satellites and planning multi-sensor integration, but no retained direct evidence or article summaries are present here. Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available. |
| 430 | Island Green Capital lowweak | Opp 0 Risk 1 | Thesis: No direct positive evidence is available, and the reviewed sources say the included summaries do not clearly establish what Island Green Capital is. Why now: No timing-based catalyst is supported because no post-recent evidence window evidence were available. Caveats: Phase2 rationale references article IDs: and: but no were provided in the reviewed sources. Reviewed evidence states summaries were about Molten Ventures and Isar Aerospace rather than clearly about Island Green Capital. Context-only mentions cannot support propagation. |
| 431 | OneWeb lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window. Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window. Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity. |
| 432 | Starfighters Space Inc. lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale describes air-launch and testing platform exposure, but no retained direct positive evidence or article summaries are provided here. Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count. Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence. |
| 433 | Starlab Space lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale notes a letter of intent related to debris removal services, but no direct retained evidence row or article summary is provided in these reviewed sources. Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window. Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis. |
| 434 | SWISSto12 lowweak | Opp 0 Risk 1 | Thesis: No supported positive thesis. The reviewed sources say SWISSto12 is only mentioned in passing in an article about SpaceLocker, which is provisional single-article context and not company-specific evidence, unavailable in reviewed sources). Why now: There is no identifiable catalyst because the reviewed sources provide only a passing mention and no direct event or fact evidence. Caveats: No current evidence is provided for. Support level is provisional single-article context only. No evidence available after recent evidence window. |
| 435 | Veact lowweak | Opp 0 Risk 1 | Thesis: No positive thesis is supported. Veact appears only via a broad funding roundup and is not linked to a space-specific category in the reviewed sources. Why now: No why-now catalyst is supported because the reviewed sources contain no post-recent evidence window evidence. Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. A broad funding roundup is not enough to establish thesis direction. Coverage data shows articles after recent evidence window = 0. |
| 436 | Volteum lowweak | Opp 0 Risk 1 | Thesis: No direct positive evidence is available. The reviewed sources only says Volteum surfaced from a general funding roundup with no space-specific linkage. Why now: No catalyst is supported in the reviewed sources due to zero post-recent evidence window evidence. Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. Funding-roundup presence alone is not directional proof. Evidence strength remains minimal. |
| 437 | Zaro lowweak | Opp 0 Risk 1 | Thesis: No reviewed sources-supported positive thesis is available. Zaro is only listed in a general funding roundup with no direct linkage to a qualifying space thesis. Why now: There is no current or durable catalyst supported by the reviewed sources because no evidence survived into the available post-recent evidence window set. Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. General funding-roundup context is weaker than direct event or fact evidence. Coverage remains insufficient for a directional call. |
| 438 | Zone14 lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be supported from the reviewed sources because there is no direct positive evidence available for Zone14 within the 90-day recent evidence window. Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence. |
Risk view
Showing rows 241-260 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 241 | AEVEX Corp. lowweak | Opp 1 Risk 1 | Thesis: No direct negative evidence is available in the reviewed sources; the main limitation is insufficient company-specific proof of role, traction, or adversity. Why now: There is no reviewed sources-grounded catalyst or timing support for a 1 year+ thesis. The reviewed sources references article id: but provides no, quote, or retained evidence row. Caveats: Sector/SPAC mention is supporting article context and weaker than direct company-specific events or facts. No representative article summary or is present for direct citation. Low scores reflect sparse evidence, not a strong directional view. |
| 242 | Agnikul Cosmos lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is provided within the reviewed sources for the selected recent evidence window, so a negative thesis is also unsupported. Why now: Why now is unsupported because the reviewed sources show zero evidence after recent evidence filtering despite many articles considered; recency-specific business state cannot be established from the provided evidence. Caveats: Coverage debug shows zero evidence after recent evidence filtering. Membership rationale cannot substitute for cited directional evidence under the output rules. Absence of evidence is not positive or negative proof. |
| 243 | Airbus SE lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources does not provide material adverse company-specific evidence within the recent evidence window, so risk is low on reviewed sources evidence but not affirmatively cleared. Why now: There is no within the recent evidence window evidence available for Airbus; the only cited article is older context published March 4, 2025, outside the 90-day cutoff noted by the reviewed sources, so recency support is weak. Caveats: Coverage after recent evidence window is effectively empty: articles after recent evidence window is 0. The available Airbus article is contextual and outside the 90-day recent evidence window. Cohort membership does not establish attractiveness. |
| 244 | Alta Ares lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supportable because the retained reviewed sources contain no direct negative evidence after recent evidence window. Why now: Why now is weak: the reviewed sources show no retained evidence after recent evidence window, and the membership rationale says Alta Ares appears only in a broad funding roundup without enough company-specific detail. Caveats: Phase-2 membership rationale references: but no article summary or direct retained evidence is available here for factual use. The reviewed sources itself says company-specific detail is insufficient. |
| 245 | Altamira Technologies Corporation lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supportable because the reviewed sources does not provide direct negative evidence for Altamira in the scoring section. Why now: The phase2 rationale notes only that Parsons acquired Altamira and references defense/national security themes, but no citable evidence are provided here. Coverage data shows zero articles after recent evidence window and zero evidence available. Caveats: Ownership/acquisition context alone is not enough without direct evidence detail. No dated catalyst evidence is surfaced in the reviewed sources. |
| 246 | Amazon.com Inc. lowweak | Opp 1 Risk 1 | Thesis: No direct adverse space-related evidence is available in the reviewed sources for Amazon within the recent evidence window. Why now: No current catalyst can be established from the available evidence because post-recent evidence window evidence are absent. Caveats: Extremely large mention universe is not conviction. No usable evidence were available after recent evidence window. |
| 247 | AnduraX lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window negative evidence is available, so a risk thesis is not evidence-supported in these reviewed sources. Why now: There is no retained article or evidence row after the 90-day recent evidence window, so the reviewed sources does not establish a current catalyst or updated business state. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and: but no or retained summaries are provided here. Scores remain low because positive or negative direction cannot be grounded with citable retained evidence. |
| 248 | Angkasa-X Holdings Corp. lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window direct negative evidence is provided in the reviewed sources, so there is not enough support for a material adverse thesis either. Why now: There is no usable within the recent evidence window article evidence available for ranking; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency-sensitive judgment is not possible from these reviewed sources alone. Caveats: Reviewed evidence notes one considered article for membership support but zero article IDs after recent evidence window and zero available evidence after recent evidence window, so ranking is constrained by evidence absence rather than business absence. Membership rationale references article: but the reviewed sources does not provide the article or a retained within the recent evidence window evidence row for ranking use. |
| 249 | Antaris Inc. lowweak | Opp 2 Risk 1 | Thesis: No material adverse thesis is supported because no direct negative evidence are provided. Why now: Why now is weak: the only reviewed sources signal is the phase2 rationale mentioning a post-Series A portfolio reference tied to article, but no representative article summary or direct evidence row is included here to establish timing or business impact. Caveats: The cited Series A context appears only in phase2 rationale rather than in stronger scoring evidence fields. No product, customer, or execution evidence is provided. |
| 250 | Applied Aerospace & Defense Inc. lowweak | Opp 1 Risk 1 | Thesis: There is also insufficient material adverse evidence in the reviewed sources to support a negative thesis. The lack of direct evidence is uncertainty, not a demonstrated business risk. Why now: Why now is weak because the reviewed sources show zero evidence available after the 90-day recent evidence window cutoff date of March 29, 2026, so recency-based catalysts cannot be established from these reviewed sources. Caveats: No current evidence is provided for cited Evidence rows available after recent evidence window: 0. Mention as competition or IPO context is weaker than direct company event evidence. |
| 251 | ArianeGroup lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources provide no direct negative evidence, so no adverse thesis is supportable from this evidence set. Why now: The phase2 rationale references Ariane 6/Arianespace launch context for Amazon Kuiper, but relation/context evidence cannot be used as counterparty propagation and no direct evidence is exposed in the scoring fields. Coverage data shows zero articles after recent evidence window and zero evidence available. Caveats: Do not use context-only relation logic as direct thesis proof. No direct company-specific event evidence is included here. |
| 252 | Arxis, Inc. lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supported within the retained 90-day evidence window; there is also no direct negative evidence available for Arxis. Why now: Why now is unclear because coverage data shows 0 articles after recent evidence window and 0 evidence after recent evidence window, so there is no retained recent catalyst evidence in the reviewed sources. Caveats: Reviewed evidence cites membership support from, but no representative article is provided, so the underlying claim cannot be restated as direct scored evidence with. Coverage after recent evidence window is empty, limiting conviction. |
| 253 | Arxis Inc. lowweak | Opp 1 Risk 1 | Thesis: No material adverse thesis is supportable from the retained reviewed sources evidence because no direct negative evidence survived the 90-day recent evidence window. Why now: Why now is weak: the reviewed sources show zero evidence after recent evidence window for Arxis Inc., so there is no current catalyst or current business-state proof in the retained record. Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references support references including: but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here. |
| 254 | Aselsan lowweak | Opp 1 Risk 1 | Thesis: No retained in-recent evidence window evidence supports a current adverse thesis. Why now: The reviewed sources retained zero evidence after the 90-day cutoff, so there is no current catalyst evidence for the 1 year+ ranking despite article-based membership context. Caveats: Membership rationale cites article, but no article summary or retained evidence row is available here. 24 articles were considered, but none remained after recent evidence filtering. |
| 255 | Astranis Space Technologies lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is available in the reviewed sources. Why now: No retained article or facts remain in the reviewed sources after recent evidence window, so timing and durability cannot be judged from local evidence. Caveats: Opportunity view depends on uncited membership rationale rather than retained evidence. No recency-confirmed direct evidence in reviewed sources. |
| 256 | Astro Digital lowweak | Opp 1 Risk 1 | Thesis: No material adverse evidence is available. Risk remains low but non-zero because the company-specific operating picture is unestablished in retained evidence. Why now: No supported current catalyst. The reviewed sources explicitly warns this is counterparty context only, and coverage debug shows no retained evidence after recent evidence window. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Counterparty context should not be treated as strong propagation evidence. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 257 | Astrobiome Space lowweak | Opp 1 Risk 1 | Thesis: No material risk thesis is supportable from retained evidence in these reviewed sources because no direct negative rows survive the recent evidence window. Why now: There is no retained evidence showing a current contract milestone, financing event, or product progress inside the recent evidence window. Caveats: Phase-2 rationale says Astrobiome Space contracted Redwire for a commercial space greenhouse/ISS agriculture mission and cites: and: but no or summaries are available here. Coverage debug shows 6 articles considered and 0 after recent evidence window. Relationship context should not be propagated as stronger evidence without direct retained event/facts. |
| 258 | Astrolight lowweak | Opp 2 Risk 1 | Thesis: The lack of retained direct evidence creates uncertainty around current contract scope, deployment status, and commercialization durability; no explicit negative evidence is available. Why now: Why now is weak because the reviewed sources cites support article: in membership rationale, but no, article summary, or retained evidence are provided after the 90-day filter. Caveats: Potentially strong fundamentals are only referenced in membership rationale without citable article details. Coverage data shows zero articles after recent evidence window and zero evidence after recent evidence window. Private-company status also limits external validation in these reviewed sources. |
| 259 | Astrome lowweak | Opp 2 Risk 1 | Thesis: No reviewed sources evidence points to material adverse developments. The constraint is evidentiary thinness, so risk remains low but uncertain. Why now: Why now is weak because the support exists only in the phase-2 rationale; coverage data shows zero evidence after recent evidence window, so timing and durability of the funding support cannot be verified from local evidence. Caveats: No direct article or event evidence is available after recent evidence window. Government-support statement is not accompanied by a dated in-window source in the reviewed sources. Low confidence due to sparse evidence. |
| 260 | Atomos Space lowweak | Opp 2 Risk 1 | Thesis: No material adverse evidence is present in the reviewed sources. Risk remains low-scored only because evidence is sparse, not because risk is disproven. Why now: Why now is limited and recency is uncertain: the only retained evidence is undated supporting context, so it cannot establish a fresh catalyst, only background relevance, article date_basis: undated). Evidence
Caveats: The evidence is undated, and the reviewed sources explicitly says to treat undated external evidence as relevance context rather than recency proof. The retained rows are weak context and neutral polarity, not positive evidence. Same article repeated rows are not independent confirmation. |